Molecular Heterogeneity of Triple Negative Breast Cancer.

ABSTRACT: Triple-negative breast cancers (TNBCs) are known to be an aggressive group of breast cancers with higher rates of relapse stage for stage compared to ER/PR positive and HER2 positive breast cancers despite optimal loco-regional and systemic therapies. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analyses identified six distinct TNBC subtypes, each displaying a unique biology. In this review we will discuss current and upcoming therapeutic strategies exploring novel approaches to targeted treatment of these TNBC subtypes.

SUBMITTER: Abramson VG 

PROVIDER: S-EPMC4235783 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature